{"drugs":["Peginterferon Beta-1a","Plegridy","Plegridy Pen","Plegridy Pen Starter Pack","Plegridy Starter Pack"],"mono":{"0":{"id":"931025-s-0","title":"Generic Names","mono":"Peginterferon Beta-1a"},"1":{"id":"931025-s-1","title":"Dosing and Indications","sub":{"0":{"id":"931025-s-1-4","title":"Adult Dosing","mono":"<b>Relapsing remitting multiple sclerosis:<\/b> initial, 63 mcg SUBQ on day 1, then 94 mcg SUBQ on day 15, then 125 mcg SUBQ on day 29; continue 125 mcg SUBQ every 14 days thereafter; may premedicate or concurrently use an antipyretic\/analgesic for flu-like symptoms "},"1":{"id":"931025-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"931025-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Relapsing remitting multiple sclerosis<br\/>"}}},"3":{"id":"931025-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931025-s-3-9","title":"Contraindications","mono":"hypersensitivity to natural or recombinant interferon beta or peginterferon, or any product component <br\/>"},{"id":"931025-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure have been reported; monitoring recommended in those with preexisting significant cardiac disease<\/li><li>Dermatologic:<\/li><li>-- injection site reactions, including necrosis, have been reported; avoid injecting near necrotic area or discontinue based on extent of necrosis; discontinue use if multiple lesions occur<\/li><li>Hematologic:<\/li><li>-- decreased peripheral blood counts, including pancytopenia and severe thrombocytopenia, have been reported; monitoring recommended particularly with myelosuppression<\/li><li>Hepatic:<\/li><li>-- hepatic injury, including hepatitis, autoimmune hepatitis, and severe hepatic failure, has been reported; monitoring recommended; consider discontinuation if condition occurs<\/li><li>-- asymptomatic elevations of hepatic transaminases have been reported with interferon beta; monitoring recommended<\/li><li>Immunologic:<\/li><li>-- anaphylaxis and serious allergic reactions have been reported with interferon beta; discontinue if condition occurs<\/li><li>-- angioedema and urticaria have been reported; discontinue if condition occurs<\/li><li>-- autoimmune disorders (eg, idiopathic thrombocytopenia, hyper- and hypothyroidism, autoimmune hepatitis) have been reported; monitoring recommended; discontinue if new autoimmune disorder occurs<\/li><li>Neurologic:<\/li><li>-- seizures have been reported; additional caution recommended with use in persons with seizure disorders<\/li><li>Psychiatric:<\/li><li>-- depression, suicidal ideation, and suicide have been reported; consider discontinuation if depression or other severe psychiatric symptoms develop<\/li><\/ul>"},{"id":"931025-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"931025-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"931025-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (62%), Injection site pain (15%), Injection site pruritus (13%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (11%)<\/li><li><b>Neurologic:<\/b>Asthenia (13%), Headache (44%)<\/li><li><b>Other:<\/b>Fever (45%), Influenza-like illness (47%), Shivering (17%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure<\/li><li><b>Dermatologic:<\/b>Injection site necrosis (Rare)<\/li><li><b>Hematologic:<\/b>Decreased lymphocyte count (Less than 1%), Decreased platelet count (Less than 1%), Decreased white blood cell count (7%), Neutropenia (Less than 1%), Pancytopenia (Rare), Thrombocytopenia (Rare)<\/li><li><b>Hepatic:<\/b>Autoimmune hepatitis, Hepatitis, Liver failure<\/li><li><b>Immunologic:<\/b>Autoimmune disease (Less than 1%)<\/li><li><b>Neurologic:<\/b>Seizure (Less than 1%)<\/li><li><b>Psychiatric:<\/b>Suicidal thoughts<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"931025-s-6","title":"Drug Name Info","sub":{"0":{"id":"931025-s-6-17","title":"US Trade Names","mono":"<ul><li>Plegridy<\/li><li>Plegridy Pen<\/li><li>Plegridy Starter Pack<\/li><li>Plegridy Pen Starter Pack<\/li><\/ul>"},"2":{"id":"931025-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Interferon, Beta (class)<\/li><\/ul>"},"3":{"id":"931025-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931025-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931025-s-7","title":"Mechanism Of Action","mono":"The exact mechanism of action of peginterferon beta-1a in patients with multiple sclerosis is unknown.<br\/>"},"8":{"id":"931025-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"931025-s-8-23","title":"Absorption","mono":"Tmax, multiple sclerosis, subQ: 1 to 1.5 days <br\/>"},"1":{"id":"931025-s-8-24","title":"Distribution","mono":"Vd, multiple sclerosis: 481 L <br\/>"},"3":{"id":"931025-s-8-26","title":"Excretion","mono":"<ul><li>Renal: extensive<\/li><li>Dialyzable, Yes (hemodialysis), 24%<\/li><li>Total body clearance: 4.1 L\/hr<\/li><\/ul>"},"4":{"id":"931025-s-8-27","title":"Elimination Half Life","mono":"approximately 78 hours <br\/>"}}},"9":{"id":"931025-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>allow to warm to room temperature for 30 minutes prior to injection<\/li><li>administer by subQ injection<\/li><li>may be self-administered<\/li><\/ul>"},"10":{"id":"931025-s-10","title":"Monitoring","mono":"<ul><li>reduction in relapse rate and disability progression is indicative of efficacy.<\/li><li>liver function tests, during therapy<\/li><li>CBC with differential, during therapy, especially in patients with myelosuppression<\/li><li>signs and symptoms of liver injury<\/li><li>signs and symptoms of cardiac disease progression; at treatment initiation and thereafter in patients with preexisting cardiac disease<\/li><li>signs and symptoms of infection, bleeding, and anemia<\/li><\/ul>"},"11":{"id":"931025-s-11","title":"How Supplied","mono":"<ul><li><b>Plegridy Pen<\/b><br\/>Subcutaneous Solution: 125 MCG\/0.5 ML<br\/><\/li><li><b>Plegridy<\/b><br\/>Subcutaneous Solution: 125 MCG\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"931025-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient to report symptoms of hepatic dysfunction, congestive heart failure, or cardiomyopathy.<\/li><li>Instruct patient to report new or worsening depression or suicidal ideation.<\/li><li>Tell patient to immediately report seizures.<\/li><li>Direct patient to report any infection, bleeding, or symptoms of anemia.<\/li><li>Side effects may include arthralgia, myalgia, asthenia, chills, headache, or pyrexia.<\/li><li>Advise patient to report serious injection site reactions (necrosis).<\/li><li>Teach patient proper technique and placement of injection.<\/li><\/ul>"}}}